| Project/Area Number |
25860069
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pharmacology in pharmacy
|
|---|
| Research Institution | Doshisha Women's College of Liberal Arts |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | アルツハイマー病 / ニューロン / 神経保護作用 / 薬理学 / ニコチン受容体 |
|---|
| Outline of Final Research Achievements |
Donepezil is widely used as a therapeutic drug for Alzheimer's disease. It prevents cortical neurons against glutamate neurotoxicity through nicotinic acetylcholine receptors, followed by the phosphatidylinositol 3-kinase (PI3K)-Akt pathway. In cortical cultures, donepezil inhibited the activation of glycogen synthase kinase-3β(GSK-3β) through the PI3K-Akt pathway. Furthermore, downstream signaling of inhibition of GSK-3β activity involved the expression level of β-catenin and site-specific tau phosphorylation, rather than the expression level of Bcl-2.
|
